ARWR vs PFE

Arrowhead Pharmaceuticals continues to demonstrate strong 10x growth potential within 3-5 years. The Q1 2026 financials (fiscal quarter ended Dec 31, 2025) showcased a significant revenue beat of $264.0M, driven by the successful commercial launch of Redemplo, and a positive net margin of 18.54%. Critically, the recently announced two-year efficacy data for plozasiran, showing an 83% triglyceride ...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...